Abbott has launched the new Afinion 2 analyser in the US to allow diabetes management through haemoglobin A1c (HbA1c) and albumin to creatinine ratio (ACR) measurements.
The next generation Afinion test system has been designed as a rapid, multi-assay platform to provide optimised and simplified results that are accurate and actionable at point-of-care.
Afinion 2 delivers HbA1c and ACR measurements in three and five minutes, respectively, which enable healthcare professionals to make rapid yet accurate medical decisions.
This fast delivery of results also provides the physicians with more time to counsel patients in one office visit.
Furthermore, the platform facilitates all-in-one connectivity to laboratory and hospital information systems (LIS/HIS), while offering a quieter experience for both clinicians and patients.
The test system can be used at physician offices, clinics, community health centres, hospitals and long-term care facilities, among other out-patient environments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Abbott Cardiometabolic and Informatics divisional vice-president Elizabeth Balthrop said: “By delivering rapid HbA1c and ACR test results, the Afinion 2 analyser does more than streamline care; its life-changing technology helps people living with diabetes get the most out of their healthcare visits.
“Within a single visit, patients can obtain real-time feedback and insights on their condition, have an informed discussion with their provider and leave with a defined care plan.”
HbA1c is used to identify average glycaemic control or blood sugar and determine the quality of diabetes management of a patient, while ACR is a kidney complications biomarker that indicates poor management of the condition.
By offering measurements for both these markers, the new system is expected to improve outcomes and minimise visits for patients.